

CSRO

COALITION OF STATE RHEUMATOLOGY ORGANIZATIONS

State Advocacy Update

Kevin Daley

Vice President, State Government Affairs

Hart Health Strategies Inc.

Agenda

- Importance of Advocacy
- CSRO state legislative priorities
- How can you help?
- CSRO Resources



Prescription Drug Affordability Board (PDABS)

- What are PDABs?
- What is CSRO doing to combat these boards?
 - Colorado – Affordability Review Comments
 - Maryland – UPL Action Plan Comments
 - Illinois – Bill Amendment
- States with PDAB legislation in 2024:
 - AZ, CO, CT, IA, IL, KY, NE, NH, NJ, MD, MI, RI, SC, VA, VT, WA, WV.

Accumulator Adjustment Programs (AAP), Maximizers, & Alternative Funding Programs (AFPs)

- All Copays Count Coalition & Alternative Funding Task Force
- AFP Project in North Carolina and Louisiana
 - AFP Study Task Force
- States with legislation in 2024:
 - CA, CO, FL, IL, LA, MA, MD, MI, MN, MO, NH, NJ, OH, OK, OR, PA, RI, UT, VT, WI

Step Therapy Reform

- State Access to Innovative Medicine (SAIM)
- CSRO Resources
 - Know the law
 - Coversheet
- Recent Wins!
 - New Mexico, New York, Vermont, and Wyoming
- State with legislation in 2024
 - MI, NJ, NM, NY, RI, VT, WY

Supporting Information for Step Therapy Exception Request	
Pursuant to §56-7-3502 , Tennessee Code Annotated	
Determination required within: <input type="checkbox"/> 2 business days	
Pursuant to §56-7-3502 , the patient qualifies for an exception to the step therapy protocol because any <u>one</u> of the following conditions has been met:	
<input type="checkbox"/> The required drug is contraindicated.	
<input type="checkbox"/> The required drug will likely cause an adverse reaction or physical or mental harm due to a documented adverse event with a previous use or documented medical condition, including a comorbid condition.	
<input type="checkbox"/> The required drug is expected to be ineffective based on the known clinical characteristics of the patient and the drug regimen.	
<input type="checkbox"/> The required drug is not in the best interest of the patient because it is expected to cause a significant barrier to adherence or compliance with a plan of care, worsen a comorbid condition, or decrease ability to achieve reasonable functional ability performing daily activities.	
<input type="checkbox"/> The patient is receiving a positive therapeutic outcome on a drug other than the required drug, and a switch to the required drug is expected to be ineffective or cause harm.	
Rationale for Request	
Signature:	Date:
Attn: Department of Commerce & Insurance Phone: 615-741-2241 / Complaint: https://www.tn.gov/commerce/resources-services/file-a-complaint.html	

PBM Reform

- What kind of legislation PBM legislation does CSRO support?
- The PBM Coalition and the Alliance for Transparent and Affordable Prescriptions (ATAP)
- States with legislation in 2024
 - AL, KY, LA, ME, MA, MD, MI, NY, NH, VA, WA

White Bagging

- **Massachusetts State Study:**
 - Remicade – Home/Specialty Pharmacy \$120 vs. Office \$90
 - Stelara – Home/Specialty Pharmacy \$228 vs. Office \$177
 - Rituxan – Home/Specialty Pharmacy \$914 vs. Office \$878
 - Orencia – Home/Specialty Pharmacy \$41 vs. Office \$42
- **Wins in 2024!**
 - Kentucky and Rhode Island
- **States with legislation in 2024:**
 - AK, CO, GA, IL, KY, LA, MD, MS, MO, NY, NE, NH, OH, OR, RI, WV.

Prior Authorization/Gold Cards

- SAIM Coalition PA Survey
- Wins in 2024!
 - Wyoming
 - Texas update?
- States with Gold Card legislation in 2024:
 - AK, AZ, CO, IN, IA, KY, MO, NE, WA, WY



Biomarker Testing

- Biomarker Coalition
- Wins in 2024!
 - CO, CT, FL, IA, PA,
- States with legislation in 2024:
 - CO, CT, HI, IA, FL, ME, MA, NV, NJ, OH, PA, WA.

Non-Medical Switching

- Win in Iowa!
 - Iowa Continuity of Care Coalition
- States with legislation in 2024:
 - AZ, FL, IA, MS, WI, WY

HOME / OPINION / GUEST COLUMNISTS

Iowa health plans don't provide stable care for chronic illness


Dr. Michael Brooks

Jan. 29, 2023 6:00 am

We all know someone — a friend, family member, maybe even yourself — who has an uncurable health condition. If untreated, these conditions can cause major disruptions to daily life or become debilitating. Often though, these conditions are manageable with proper treatment. As a rheumatologist, I work with Iowans to find treatments that work for conditions like rheumatoid arthritis and lupus. And I see firsthand what happens when treatments that work are taken away by patients' health plans.

How can you help?

- CSRO Action Center
- Committee Testimony
- Op-eds
- Capitol Day



The screenshot shows the CSRO website's navigation menu with 'ADVOCACY' selected. A dropdown menu is open, listing 'OUR ISSUES', 'LEGISLATIVE MAP TOOL', and 'ACTION CENTER'. The 'ACTION CENTER' page is displayed, featuring a header 'Action Center' and a sub-header 'Welcome to the CSRO Action Center'. The main text explains the platform's purpose: 'With so many concerns to track, legislators rely on you to raise the profile of pressing issues. This page houses CSRO's engagement platform, which allows you to communicate directly with your legislators. Advocacy is important, but we are also mindful of your time. Our tool allows you to participate in grassroots advocacy with minimal time expenditure.' Below this are two featured articles: 'FEDERAL: SUPPORT PBM REFORM' with an image of the US Capitol and 'New Jersey - Coverage for Biomarker Testing' with a megaphone icon. On the right side, there are two sign-up sections: 'View Your Election Center' with a ZIP Code input field and a right arrow icon, and 'Sign Up for Alerts' with an 'Enter Email' input field and a ZIP Code input field with a right arrow icon.

Policy Correspondence

CONFERENCE MEMBERSHIP FELLOWS ADVOCACY **RESOURCES** NEWS ABOUT

ADVOCACY RESOURCES
MEMBER RESOURCES
EMPLOYER RESOURCES
EDUCATION LIBRARY
POLICY CORRESPONDENCE
CAREER CENTER
REPORTING INSURANCE/PAYER ISSUES

State Legislation Correspondence


CSRO actively advocates on the state level, focusing on educating legislators and policy officials on the impact that policy and legislation have to the patient's quality of care and disease management options – both before and after CSRO has submitted.

For more information about proposed and enacted policy in your state, visit [www.csro.info](#)

2024 Comments

- **Iowa** – [CSRO Letter RE: HF 626](#) (Non-Medical Switching)
- **California** – SB 966 Comments (Rebate Pass Through)
 - [August, 15, 2024](#)
 - [September 4, 2024](#)
- **Colorado** – [CSRO Letter RE: HB 1010](#) (White Bagging)
- **Colorado** – [CSRO Letter RE: Drug Affordability Review](#)
- **Maine** – [CSRO Letter RE: LD 1165](#) (Rebate Pass Through)

CSRO Map Tool



CSRO

COALITION OF STATE RHEUMATOLOGY ORGANIZATIONS

Federal Advocacy Update

Matt Duckworth

Vice President, Government Relations

Hart Health Strategies Inc.

Agenda

- Perspective
- How we got here, where we're going
- CSRO federal legislative priorities

Perspective



The Present



Outlook



Shameless Plug!



CSRO

COALITION OF STATE RHEUMATOLOGY ORGANIZATIONS

Questions?

WEBSITE

www.csro.info

EMAIL

info@csro.info

PHONE

414.918.9825